Common Cabozantinib Adverse Events: Management and Impact on Outcomes and Treatment Duration in Advanced Renal Cell Carcinoma, Hepatocellular Carcinoma, and Radioiodine-Refractory Differentiated Thyroid Cancer
Häufige Cabozantinib-Nebenwirkungen: Management und Einfluss auf Outcomes und Behandlungsdauer bei fortgeschrittenem Nierenzellkarzinom, hepatozellulärem Karzinom und radioiodidrefraktärem differenziertem Schilddrüsenkarzinom
Journal of the Advanced Practitioner in Oncology · 09.11.2026 · 17 (7)
DOI: 10.6004/jadpro.2026.17.7.30 ↗Auf einen Blick
In 3 Studien mit Cabozantinib waren die häufigsten Grad-3/4-Nebenwirkungen Hypertonie, Hand-Fuß-Syndrom, Diarrhö und Fatigue. PFS und Behandlungsdauer waren bei Patient:innen mit Grad-≥3-AE ähnlich wie in der Gesamtpopulation.
Fragestellung
Welchen Einfluss haben Cabozantinib-assoziierte Nebenwirkungen auf PFS und Behandlungsdauer in diesen 3 Indikationen?
Methode
Post-hoc-Analyse von 3 zulassungsrelevanten Monotherapie-Studien (METEOR, CELESTIAL, COSMIC-311); Vergleich von PFS und Behandlungsdauer; Auswertung häufiger AEs mit Dosisanpassungen.
Ergebnisse
923 mit Cabozantinib behandelte Patient:innen. Häufigste Grad-3/4-AEs in allen 3 Studien: Hypertonie 15 %, palmar-plantarerythrodysästhetisches Syndrom 13 %, Diarrhö 10 %, Fatigue 10 %. PFS und Behandlungsdauer waren ähnlich; Abbruchraten wegen einzelner häufiger AEs < 3 %.
Schlussfolgerung der Autor:innen
Cabozantinib zeigte über die Indikationen hinweg ein konsistentes Sicherheitsprofil. Mit proaktiver AE-Management-Strategie waren PFS und Behandlungsdauer bei Patient:innen mit Grad-≥3-AEs ähnlich wie in der Gesamtpopulation.
Kernaussagen
- Häufigste Grad-3/4-AEs: Hypertonie, Hand-Fuß-Syndrom, Diarrhö, Fatigue
- PFS und Behandlungsdauer bei Grad-≥3-AEs ähnlich
- Abbrüche wegen häufiger AEs waren selten (< 3 %)
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
Kurz gefasst
Fachartikel in der Zeitschrift Journal of the Advanced Practitioner in Oncology, online erschienen am 09.11.2026. Verfasst von Steven Lee-Ramos und 23 weiteren Autor:innen.
Themen: Patientensicherheit
Abstract (Originalsprache)
Background
Cabozantinib, a tyrosine kinase inhibitor, is a standard-of-care therapy for previously treated advanced renal cell carcinoma, hepatocellular carcinoma, and radioiodine-refractory differentiated thyroid cancer. We evaluated the impact of cabozantinib-associated adverse events (AEs) on treatment outcomes in these populations. Here we report our findings and discuss AE management.
Methods
In this post-hoc analysis of three cabozantinib monotherapy pivotal studies (METEOR, CELESTIAL, and COSMIC-311), we compared progression-free survival (PFS) and treatment duration between patients who experienced ≥ 1 any-cause grade ≥ 3 AE and the overall population in the cabozantinib arm of each study. We characterized the most common any-cause AEs leading to dose modification, and advanced practitioner authors provided AE management strategies.
Results
Of 923 cabozantinib-treated patients across the studies, the most common grade 3/4 AEs occurring in ≥ 10% of patients in all three studies combined were hypertension (15%), palmar-plantar erythrodysesthesia syndrome (13%), diarrhea (10%), and fatigue (10%). In each trial, median PFS was similar in patients with a grade ≥ 3 AE vs. the respective overall study populations; treatment durations were also similar. Among the four most common any-grade AEs leading to dose modifications, discontinuation rates due to each event were low (< 3%). Advanced practitioner–led AE management strategies included prophylaxis, monitoring, supportive care, and dose modifications.
Conclusions
Cabozantinib has a consistent safety profile across indications. With proactive management, patients experiencing grade ≥ 3 AEs had similar PFS outcomes and treatment durations as the overall study populations. Advanced practitioner–led proactive AE management can allow patients to remain on therapy and maximize clinical benefits.
Zitieren
APA
Lee-Ramos, S., MS, RN, AGACNP-BC, Seery, V., MSN, RN, ANP-BC, AOCNP, Andresen, D., MSN, APN-C, AOCNP, Williamson, D., MPH, Berry, N., PhD, Hall, T., PhD, …, & AOCNP (2026). Common Cabozantinib Adverse Events: Management and Impact on Outcomes and Treatment Duration in Advanced Renal Cell Carcinoma, Hepatocellular Carcinoma, and Radioiodine-Refractory Differentiated Thyroid Cancer. Journal of the Advanced Practitioner in Oncology, 17(7). https://doi.org/10.6004/jadpro.2026.17.7.30
Vancouver
Lee-Ramos S, MS, RN, AGACNP-BC, Seery V, MSN, et al. Common Cabozantinib Adverse Events: Management and Impact on Outcomes and Treatment Duration in Advanced Renal Cell Carcinoma, Hepatocellular Carcinoma, and Radioiodine-Refractory Differentiated Thyroid Cancer. Journal of the Advanced Practitioner in Oncology. 2026;17(7). doi:10.6004/jadpro.2026.17.7.30
BibTeX
@article{LeeRamos2026,
author = {Lee-Ramos, Steven and MS and RN and AGACNP-BC and Seery, Virginia and MSN and RN and ANP-BC and AOCNP and Andresen, Diane and MSN and APN-C and AOCNP and Williamson, Denise and MPH and Berry, Nicholas and PhD and Hall, Tasha and PhD and RN and Martone, Brenda and MSN and ANP-BC and AOCNP},
title = {Common Cabozantinib Adverse Events: Management and Impact on Outcomes and Treatment Duration in Advanced Renal Cell Carcinoma, Hepatocellular Carcinoma, and Radioiodine-Refractory Differentiated Thyroid Cancer},
journal = {Journal of the Advanced Practitioner in Oncology},
year = {2026},
volume = {17},
number = {7},
doi = {10.6004/jadpro.2026.17.7.30}
}
EUVIMED